BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 14, Issue 4
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2025.
World J Nephrol. Dec 25, 2025; 14(4): 109457
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.109457
Figure 2
Full Size Figure Download Figure
Figure 2 Potential kidney-cardiovascular and metabolic effects of semaglutide in people with chronic kidney disease. ANP: Atrial natriuretic peptide; BP: Blood pressure; CKD: Chronic kidney disease; CV: Cardiovascular; HbA1c: Glycated haemoglobin; KIM-1: Kidney injury molecule-1; LDL-C: Low-density lipoprotein cholesterol; NF-κB: Nuclear factor-κB; NHE3: Sodium-hydrogen exchanger-3; NO: Nitric oxide; RAAS: Renin-angiotensin-aldosterone system; RAGE: Receptor for advanced glycation end products; TGF-β: Transforming growth factor-β. Created in BioRender (https://BioRender.com/yd9812v).
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.